Identifying Key Epigenetic Modification-Related Genes for Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma and Cellular Validation.

IF 4.1 4区 医学 Q2 GENETICS & HEREDITY
Huizhen Zhang, Junjie Li, Heng Xu, ShiSong Zhang, Yunkun Lu, Sijie Feng
{"title":"Identifying Key Epigenetic Modification-Related Genes for Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma and Cellular Validation.","authors":"Huizhen Zhang, Junjie Li, Heng Xu, ShiSong Zhang, Yunkun Lu, Sijie Feng","doi":"10.2174/0115665232432474251103064112","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (CESC) is a highly prevalent female malignancy. As the epigenomic characteristics of immune cells and cancer cells can serve as predictive indicators for the response to cancer immunotherapy, analysis of epigenetically modified genes (EpiGenes) could contribute to CESC treatment.</p><p><strong>Methods: </strong>The ssGSEA algorithm was employed to compute EpiGenes scores. Core genes that exhibited significant module association and a close correlation with EpiGenes scores were identified via the WGCNA package. Univariate Cox proportional hazards regression was performed on the core genes using the survival package, followed by gene set reduction via LASSO Cox regression. Ultimately, key genes were determined through multivariate Cox regression to establish a RiskScore model. Further, the optimal risk cutoff was determined using the survminer package to stratify CESC patients into high- and low-risk subgroups. For enrichment analysis, clusterProfiler and GSEA were utilized. Immune infiltration across risk groups was evaluated via ssGSEA, the MCPcounter algorithm, and the ESTIMATE algorithm. TIDE was employed to compare immunotherapeutic responses between the risk groups, while the pRRophetic software was utilized to predict patients' chemotherapeutic drug sensitivity. The biomarkers identified were validated by performing in vitro experiments.</p><p><strong>Results: </strong><i>CEP78, DOCK7, DPY19L4</i>, and <i>POM121</i> were identified by computational analyses as the key genes for CESC and further validated through <i>in vitro</i> experiments. Pathway enrichment analysis revealed predominant enrichment in immune-related pathways in the high-risk group, whereas the low-risk group was more enriched in energy and metabolic pathways. A significant negative correlation was observed between CD8+ T cell abundance and RiskScore, with higher ESTIMATEScores and StromalScores in high-risk patients. Notably, the high-risk group also demonstrated lower potential sensitivity to immunotherapy but more active responsiveness to a broader spectrum of chemotherapeutic agents.</p><p><strong>Discussion: </strong>Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis revealed that module genes are significantly enriched in cell cycle regulatory pathways, and these genes, in conjunction with Human Papillomavirus (HPV) infection-induced cell cycle dysregulation, jointly participate in CESC pathogenesis, providing a mechanistic basis for understanding the disease.</p><p><strong>Conclusion: </strong>This study provided novel theoretical evidence for immunotherapy and chemotherapy selection in the management of CESC.</p>","PeriodicalId":10798,"journal":{"name":"Current gene therapy","volume":" ","pages":"1-13"},"PeriodicalIF":4.1000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current gene therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115665232432474251103064112","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (CESC) is a highly prevalent female malignancy. As the epigenomic characteristics of immune cells and cancer cells can serve as predictive indicators for the response to cancer immunotherapy, analysis of epigenetically modified genes (EpiGenes) could contribute to CESC treatment.

Methods: The ssGSEA algorithm was employed to compute EpiGenes scores. Core genes that exhibited significant module association and a close correlation with EpiGenes scores were identified via the WGCNA package. Univariate Cox proportional hazards regression was performed on the core genes using the survival package, followed by gene set reduction via LASSO Cox regression. Ultimately, key genes were determined through multivariate Cox regression to establish a RiskScore model. Further, the optimal risk cutoff was determined using the survminer package to stratify CESC patients into high- and low-risk subgroups. For enrichment analysis, clusterProfiler and GSEA were utilized. Immune infiltration across risk groups was evaluated via ssGSEA, the MCPcounter algorithm, and the ESTIMATE algorithm. TIDE was employed to compare immunotherapeutic responses between the risk groups, while the pRRophetic software was utilized to predict patients' chemotherapeutic drug sensitivity. The biomarkers identified were validated by performing in vitro experiments.

Results: CEP78, DOCK7, DPY19L4, and POM121 were identified by computational analyses as the key genes for CESC and further validated through in vitro experiments. Pathway enrichment analysis revealed predominant enrichment in immune-related pathways in the high-risk group, whereas the low-risk group was more enriched in energy and metabolic pathways. A significant negative correlation was observed between CD8+ T cell abundance and RiskScore, with higher ESTIMATEScores and StromalScores in high-risk patients. Notably, the high-risk group also demonstrated lower potential sensitivity to immunotherapy but more active responsiveness to a broader spectrum of chemotherapeutic agents.

Discussion: Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis revealed that module genes are significantly enriched in cell cycle regulatory pathways, and these genes, in conjunction with Human Papillomavirus (HPV) infection-induced cell cycle dysregulation, jointly participate in CESC pathogenesis, providing a mechanistic basis for understanding the disease.

Conclusion: This study provided novel theoretical evidence for immunotherapy and chemotherapy selection in the management of CESC.

宫颈鳞状细胞癌和宫颈内膜腺癌关键表观遗传修饰相关基因的鉴定及细胞验证。
宫颈鳞状细胞癌和宫颈内膜腺癌(CESC)是一种非常普遍的女性恶性肿瘤。由于免疫细胞和癌细胞的表观基因组特征可以作为癌症免疫治疗反应的预测指标,因此分析表观遗传修饰基因(EpiGenes)可能有助于CESC的治疗。方法:采用ssGSEA算法计算EpiGenes评分。通过WGCNA包鉴定出与EpiGenes评分密切相关的核心基因。使用生存包对核心基因进行单因素Cox比例风险回归,然后通过LASSO Cox回归减少基因集。最终通过多变量Cox回归确定关键基因,建立RiskScore模型。此外,使用survminer包确定最佳风险临界值,将CESC患者分为高风险和低风险亚组。富集分析使用了clusterProfiler和GSEA。通过ssGSEA、MCPcounter算法和ESTIMATE算法评估风险组间的免疫浸润。采用TIDE比较危险组之间的免疫治疗反应,使用prorophetic软件预测患者的化疗药物敏感性。鉴定的生物标志物通过体外实验进行验证。结果:通过计算分析确定CEP78、DOCK7、DPY19L4和POM121为CESC的关键基因,并通过体外实验进一步验证。途径富集分析显示,高危组主要富集免疫相关途径,而低危组则更多富集能量和代谢途径。CD8+ T细胞丰度与RiskScore呈显著负相关,高危患者的ESTIMATEScores和StromalScores较高。值得注意的是,高危组对免疫治疗的潜在敏感性较低,但对更广泛的化疗药物有更积极的反应。讨论:京都基因与基因组百科(KEGG)富集分析显示,模块基因在细胞周期调控通路中显著富集,这些基因与人乳头瘤病毒(HPV)感染诱导的细胞周期失调共同参与CESC的发病机制,为认识该疾病提供了机制基础。结论:本研究为CESC的免疫治疗和化疗选择提供了新的理论依据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current gene therapy
Current gene therapy 医学-遗传学
CiteScore
6.70
自引率
2.80%
发文量
46
期刊介绍: Current Gene Therapy is a bi-monthly peer-reviewed journal aimed at academic and industrial scientists with an interest in major topics concerning basic research and clinical applications of gene and cell therapy of diseases. Cell therapy manuscripts can also include application in diseases when cells have been genetically modified. Current Gene Therapy publishes full-length/mini reviews and original research on the latest developments in gene transfer and gene expression analysis, vector development, cellular genetic engineering, animal models and human clinical applications of gene and cell therapy for the treatment of diseases. Current Gene Therapy publishes reviews and original research containing experimental data on gene and cell therapy. The journal also includes manuscripts on technological advances, ethical and regulatory considerations of gene and cell therapy. Reviews should provide the reader with a comprehensive assessment of any area of experimental biology applied to molecular medicine that is not only of significance within a particular field of gene therapy and cell therapy but also of interest to investigators in other fields. Authors are encouraged to provide their own assessment and vision for future advances. Reviews are also welcome on late breaking discoveries on which substantial literature has not yet been amassed. Such reviews provide a forum for sharply focused topics of recent experimental investigations in gene therapy primarily to make these results accessible to both clinical and basic researchers. Manuscripts containing experimental data should be original data, not previously published.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书